Bladder cancer combo shows promise in Real-World review
NCT ID NCT07420855
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks back at how well a combination of two drugs—enfortumab vedotin and pembrolizumab—works as the first treatment for people with advanced bladder cancer that has spread. Researchers will collect data from 361 patients around the world to see how long they live and how the cancer responds. The goal is to learn from real-world experience, not to test a new drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
enfortumab vedotin plus pembrolizumab
What this could lead to
If successful, this study could confirm that this drug combination works well as a first treatment for advanced bladder cancer, potentially improving survival and guiding future standard care.
What could go wrong
This is a retrospective study, meaning it looks back at past treatments rather than testing a new approach. Results may be less reliable than a controlled trial, and the combination can cause serious side effects like immune reactions or nerve damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ospedale di Macerata
Province of Macerata, 62100, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••